120 related articles for article (PubMed ID: 21204728)
1. The kinase NIK as a therapeutic target in multiple myeloma.
Gardam S; Beyaert R
Expert Opin Ther Targets; 2011 Feb; 15(2):207-18. PubMed ID: 21204728
[TBL] [Abstract][Full Text] [Related]
2. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells.
Odqvist L; Sánchez-Beato M; Montes-Moreno S; Martín-Sánchez E; Pajares R; Sánchez-Verde L; Ortiz-Romero PL; Rodriguez J; Rodríguez-Pinilla SM; Iniesta-Martínez F; Solera-Arroyo JC; Ramos-Asensio R; Flores T; Palanca JM; Bragado FG; Franjo PD; Piris MA
Clin Cancer Res; 2013 May; 19(9):2319-30. PubMed ID: 23536439
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells.
Saitoh Y; Martínez Bruyn VJ; Uota S; Hasegawa A; Yamamoto N; Imoto I; Inazawa J; Yamaoka S
Lung Cancer; 2010 Dec; 70(3):263-70. PubMed ID: 20338663
[TBL] [Abstract][Full Text] [Related]
4. Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Mazzera L; Abeltino M; Lombardi G; Cantoni AM; Ria R; Ricca M; Saltarella I; Naponelli V; Rizzi FMA; Perris R; Corradi A; Vacca A; Bonati A; Lunghi P
Haematologica; 2019 Dec; 104(12):2465-2481. PubMed ID: 30948493
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways.
Jang SI; Kim HJ; Kim YJ; Jeong SI; You YO
Eur J Pharmacol; 2006 Aug; 542(1-3):1-7. PubMed ID: 16797002
[TBL] [Abstract][Full Text] [Related]
6. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice.
Yin L; Wu L; Wesche H; Arthur CD; White JM; Goeddel DV; Schreiber RD
Science; 2001 Mar; 291(5511):2162-5. PubMed ID: 11251123
[TBL] [Abstract][Full Text] [Related]
7. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway.
Ninomiya-Tsuji J; Kishimoto K; Hiyama A; Inoue J; Cao Z; Matsumoto K
Nature; 1999 Mar; 398(6724):252-6. PubMed ID: 10094049
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of Ginkgolids (A+B) is associated with inhibition of NIK/IKK/IkappaB/NF-kappaB signaling pathway in a rat model of permanent focal cerebral ischemia.
Wang X; Qin ZH; Shi H; Savitz SI; Qin AP; Jiang Y; Zhang HL
Brain Res; 2008 Oct; 1234():8-15. PubMed ID: 18722355
[TBL] [Abstract][Full Text] [Related]
9. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma).
Nuñez C; Cansino JR; Bethencourt F; Pérez-Utrilla M; Fraile B; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
Histopathology; 2008 Aug; 53(2):166-76. PubMed ID: 18752500
[TBL] [Abstract][Full Text] [Related]
10. NIK is a component of the EGF/heregulin receptor signaling complexes.
Chen D; Xu LG; Chen L; Li L; Zhai Z; Shu HB
Oncogene; 2003 Jul; 22(28):4348-55. PubMed ID: 12853971
[TBL] [Abstract][Full Text] [Related]
11. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
12. Induction of nuclear factor-kappaB activation through TAK1 and NIK by diesel exhaust particles in L2 cell lines.
Yun YP; Joo JD; Lee JY; Nam HY; Kim YH; Lee KH; Lim CS; Kim HJ; Lim YG; Lim Y
Toxicol Lett; 2005 Feb; 155(2):337-42. PubMed ID: 15603929
[TBL] [Abstract][Full Text] [Related]
13. Molecular mediators of alphavbeta3-induced endothelial cell survival.
Rice J; Courter DL; Giachelli CM; Scatena M
J Vasc Res; 2006; 43(5):422-36. PubMed ID: 16888388
[TBL] [Abstract][Full Text] [Related]
14. TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.
Kanno Y; Sakurai D; Hase H; Kojima H; Kobata T
J Recept Signal Transduct Res; 2010 Apr; 30(2):121-32. PubMed ID: 20184394
[TBL] [Abstract][Full Text] [Related]
15. Regulation of late B cell differentiation by intrinsic IKKalpha-dependent signals.
Mills DM; Bonizzi G; Karin M; Rickert RC
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6359-64. PubMed ID: 17404218
[TBL] [Abstract][Full Text] [Related]
16. Non-canonical NF-κB signaling activation and regulation: principles and perspectives.
Razani B; Reichardt AD; Cheng G
Immunol Rev; 2011 Nov; 244(1):44-54. PubMed ID: 22017430
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways.
Leghmari K; Bennasser Y; Bahraoui E
Eur J Cell Biol; 2008 Dec; 87(12):947-62. PubMed ID: 18760861
[TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.
Demchenko YN; Brents LA; Li Z; Bergsagel LP; McGee LR; Kuehl MW
Oncotarget; 2014 Jun; 5(12):4554-66. PubMed ID: 24980832
[TBL] [Abstract][Full Text] [Related]
19. [Molecular pathogenesis of myeloma for the therapeutic targets].
Hanamura I
Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK).
Zhang S; Shan C; Kong G; Du Y; Ye L; Zhang X
Oncogene; 2012 Aug; 31(31):3607-20. PubMed ID: 22105365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
